| 引用本文:鲍岩岩1，时宇静1，高英杰1，周利润1，耿子涵1，姚荣妹1，郭姗姗1，包蕾1，韩冰2，葛一蒙2，崔晓兰1.复方芩兰口服液防治副流感病毒感染药效学研究[J].世界中医药,2022,(15):. |
|
| 复方芩兰口服液防治副流感病毒感染药效学研究 |
| Pharmacodynamics of Compound Qinlan Oral Liquid in Preventing and Treating Parainfluenza Virus Infection |
| 投稿时间：2020-06-30 |
| DOI：10.3969/j.issn.1673-7202.2022.15.015 |
| 中文关键词: 复方芩兰口服液 副流感病毒 ICR小鼠 药效作用 肺指数 肺炎 支气管 免疫因子 |
| English Keywords:Compound Qinlan Oral Liquid Parainfluenza virus ICR mice Pharmacodynamic effect Lung index Pneumonia Bronchus Immune factor |
| 基金项目:国家自然科学基金面上项目（81873072）；中国中医科学院科技创新工程项目(CI2021A04608) |
|
| 摘要点击次数: 493 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的:评价复方芩兰口服液防治副流感病毒感染的药效作用,并针对药效结果开展组织病理学、血清和肺组织匀浆免疫因子高通量筛选研究。方法:采用副流感病毒(仙台株)感染ICR小鼠模型,观察复方芩兰口服液对该模型小鼠的治疗作用,并探讨其对该模型小鼠肺组织病理改变、血清及肺组织免疫因子含量的影响。结果:复方芩兰口服液高剂量[22 mL/(kg·d)]能显著降低模型小鼠肺指数(P<005),高剂量[22 mL/(kg·d)]、中剂量[11 mL/(kg·d)]、低剂量[55 mL/(kg·d)]组肺指数抑制率分别为4947%、2968%、1846%,且抑制率显示出了量效关系;复方芩兰口服液高剂量[22 mL/(kg·d)]、中(11 mL/(kg·d)剂量可以显著改善模型小鼠肺支气管病变(P<005);复方芩兰口服液高剂量[22 mL/(kg·d)]可以显著降低血清免疫因子诱导蛋白-10（IP-10)、单核细胞趋化蛋白-3(MCP-3)、巨噬细胞炎症蛋白-1α(MIP-1α)、RANTES、嗜酸性粒细胞趋化因子含量(P<005),中剂量[11 mL/(kg·d)]可以显著降低血清免疫因子MCP-3含量(P<005);复方芩兰口服液高剂量[22 mL/(kg·d)]可以显著降低肺组织免疫因子生长调节癌基因(GRO)-α、MCP-1、MCP-3、MIP-2、IP-10、MIP-1α、MIP-1β、RANTES含量(P<005),中剂量[11 mL/(kg·d)]可以显著降低肺组织免疫因子GRO-α、MCP-1、MCP-3、MIP-2含量(P<005),低剂量[55 mL/(kg·d)]可以显著降低肺组织免疫因子GRO-α含量(P<005)。结论:复方芩兰口服液对副流感病毒感染肺炎有一定的治疗作用,可以改善肺支气管病变,降低血清及肺组织免疫因子含量。 |
| English Summary: |
| To evaluate the efficacy of Compound Qinlan Oral Liquid in preventing and treating parainfluenza virus infection based on histopathology and the immune factors in serum and lung tissue homogenate.Methods:ICR mouse model was established by infection with parainfluenza virus(Sendai strain).Compound Qinlan Oral Liquid was administrated in high [22 mL/(kg·d)]，medium [11 mL/(kg·d)]，and low [55 mL/(kg·d)] doses，respectively.The therapeutic effect of Compound Qinlan Oral Liquid on the model mice was evaluated based on the pathological changes of lung tissue，as well as the levels of immune factors in the serum and lung tissue.Results:The high dose group reduced the lung index of model mice(P<005).The high，medium，and low dose groups decreased the lung index by 4947%，2968%，and 1846%，respectively，which showed a dose-dependent manner.The high and medium doses alleviated the bronchial lesions in model mice(P<005).The high dose group reduced the levels of inducible protein-10(IP-10)，monocyte chemoattractant protein(MCP)-3，macrophage inflammatory ptotein(MIP)-1α，RANTES，and Eotaxin(P<005)，and the medium dose group lowered that of MCP-3(P<005) in the serum.The high dose group reduced growth-related oncogene(GRO)-α，MCP-1，MCP-3，MIP-2，IP-10，MIP-1α，MIP-1β，and RANTES(P<005); the medium dose group reduced GRO-α，MCP-1，MCP-3，and MIP-2(P<005); and the low dose group reduced GRO-α(P<005) in the lung tissue.Conclusion:Compound Qinlan Oral Liquid has therapeutic effect on the pneumonia caused by parainfluenza virus infection，which can alleviate pulmonary bronchial lesions and reduce the immune factors in the serum and lung tissue. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
